Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community
JAMA, 07/02/09
Melander O et al. – Selected biomarkers may be used to predict future cardiovascular events, but the gains over conventional risk factors are minimal. Risk classification improved in intermediate-risk individuals, mainly through the identification of those unlikely to develop events.
Methods- Study of the utility of contemporary biomarkers for predicting cardiovascular risk when added to conventional risk factors
- Cohort study of 5067 pts (mean age, 58 yrs; 60% women) without cardiovascular disease from Malmö, Sweden, who had baseline examination between 1991-1994
- Measurement of C-reactive protein (CRP), cystatin C, lipoprotein-associated phospholipase 2, midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide, and N-terminal pro-B-type natriuretic peptide (N-BNP)
- Follow-up until 2006 using Swedish national hospital discharge and cause-of-death registers and the Stroke in Malmö register for first cardiovascular events (myocardial infarction, stroke, coronary death)
- Main outcome measures: incident cardiovascular and coronary events
- During median follow-up of 12.8 yrs, 418 cardiovascular and 230 coronary events
- Models with conventional risk factors had C statistics of 0.758 and 0.760 for cardiovascular and coronary events, respectively
- Biomarkers retained in backward-elimination models were CRP and N-BNP for cardiovascular events and MR-proADM and N-BNP for coronary events, which increased C statistic by 0.007 and 0.009, respectively
- Modest proportion of pts reclassified: 8% for cardiovascular risk, 5% for coronary risk
- Net reclassification improvement: nonsignificant for cardiovascular events and coronary events
- Greater improvements in analyses restricted to intermediate-risk pts
- Correct reclassification almost entirely confined to down-classification of pts without events vs up-classification of pts with events
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis
Arthritis Care and Research , 11/03/09
Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment
Cardiovascular Drugs and Therapy, 11/03/09
Today in Coronary Artery Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Acute Coronary Syndromes: Diagnosis and Management, Part I
Mayo Clinic Proceedings, 10/05/09
Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in older patients
Archives of Gerontology and Geriatrics, 10/14/09
Carbohydrate-restricted diets for obesity and related diseases: An update
Current Atherosclerosis Reports, 11/17/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


